Esperion Therapeutics Stock Forecast for 2023 - 2025 - 2030
Updated on 04/23/2024
Esperion Therapeutics Stock Forecast and Price Target
Esperion Therapeutics's stock is projected to advance by 282.78% from the previous closing price if it reaches the average target of $8.00 by the year's end, as reputable analysts recently projected. This potential upside is calculated on a high-end estimate of $16.00 and a low-end estimate of $2.90. If you are looking to invest in the stock, it's important to research and compare different companies.
282.78% Upside
Esperion Therapeutics Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Esperion Therapeutics's Price has grown by 100.00%, rising from $0.00 to $0.00. For the next year, analysts predict that Fair Value will reach $2.25 – an increase of 100.00%. Over the next seven years, experts believe that Esperion Therapeutics's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$745.69 | Buy/Sell | $636.99 | 12.31% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$149.56 | Buy/Sell | $174.55 | 13.67% |
| MRK Stock Forecast | Merck | Outperform |
2
|
$126.88 | Buy/Sell | $130.51 | 9.95% |
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$26.32 | Buy/Sell | $32.87 | 15.88% |
| VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
12
|
$404.91 | Buy/Sell | $457.59 | 11.14% |
Esperion Therapeutics Revenue Forecast for 2023 - 2025 - 2030
Esperion Therapeutics's Revenue has decreased by 48.88% In the last three years, from $227.55M to $116.33M. For the next year, analysts predict that Revenue will reach $343.10M – an increase of 194.94%. Over the next seven years, experts believe that Esperion Therapeutics's Revenue will grow at a rate of 674.52%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$48.99 | Buy/Sell | $58.15 | 12.27% |
| REGN Stock Forecast | Regeneron Pharmaceuticals | Outperform |
2
|
$907.32 | Buy/Sell | $961.26 | 15.73% |
| ZTS Stock Forecast | Zoetis | Outperform |
18
|
$149.56 | Buy/Sell | $220.47 | 47.77% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$41.02 | Buy/Sell | $44.86 | 9.70% |
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$146.07 | Buy/Sell | $245.24 | 47.19% |
| VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$11.36 | Buy/Sell | $11.73 | 5.63% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| UTHR Stock Forecast | United Therapeutics | Outperform |
12
|
$234.47 | Buy/Sell | $284.08 | 26.67% |
| CTLT Stock Forecast | Catalent | Hold |
15
|
$56.03 | Buy/Sell | $49.29 | 13.33% |
| CYTK Stock Forecast | Cytokinetics | Outperform |
10
|
$65.57 | Buy/Sell | $87.92 | 43.36% |
Esperion Therapeutics EBITDA Forecast for 2023 - 2025 - 2030
Esperion Therapeutics's EBITDA has seen growth In the last three years, going from $-120.85M to $-155.35M – a gain of 28.55% For the next year, 2 analysts project Esperion Therapeutics's EBITDA to drop by 289.21%, reaching $293.93M. By 2030, professionals believe that Esperion Therapeutics's EBITDA will decrease by 694.48%, reaching $923.53M – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IONS Stock Forecast | Ionis Pharmaceuticals | Outperform |
9
|
$41.84 | Buy/Sell | $55.60 | 43.88% |
| MDGL Stock Forecast | Madrigal Pharmaceuticals | Outperform |
4
|
$218.38 | Buy/Sell | $315.92 | 78.59% |
| BCPC Stock Forecast | Balchem | Outperform |
18
|
$145.07 | Buy/Sell | $145.00 | 12.36% |
Esperion Therapeutics EBIT Forecast for 2023 - 2025 - 2030
In the last three years, EBIT for Esperion Therapeutics has grown by 28.14%, going from $-121.40M to $-155.56M. According to 6 prominent analysts, Esperion Therapeutics's EBIT will fall by 172.90% in the next year, reaching $113.40M. By 2030, professionals believe that Esperion Therapeutics's EBIT will decrease by 449.06%, reaching $543.00M – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PRGO Stock Forecast | Perrigo Co PLC | Outperform |
16
|
$30.49 | Buy/Sell | $44.75 | 29.88% |
| NEOG Stock Forecast | Neogen | Outperform |
16
|
$12.31 | Buy/Sell | $37.00 | 38.10% |
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£15.20 | Buy/Sell | £28.89 | 107.24% |
Esperion Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Esperion Therapeutics's EPS has grown by 100.00%, rising from $-5.23 to $0.00. For the next year, analysts predict that EPS will reach $0.20 – an increase of 100.00%. Over the next seven years, experts believe that Esperion Therapeutics's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CORT Stock Forecast | Corcept Therapeutics | Buy |
16
|
$23.00 | Buy/Sell | $35.67 | 65.22% |
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Buy |
14
|
$8.31 | Buy/Sell | $17.83 | 104.57% |
| TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$14.25 | Buy/Sell | $29.44 | 138.60% |
Site Navigation
.jpg)